Zasocitinib (TAK-279), a Selective, Oral TYK2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis. J of Skin [Internet]. 2024 Nov. 18 [cited 2025 Apr. 4];8(6):s441. Available from: https://skin.dermsquared.com/skin/article/view/3139